“Off-Label” for Pain

 

Using a drug a lot more for what it’s NOT approved for.  This is Dr. Steven Andrew Davis, Speaking of Health.  Every FDA-approved prescription drug is “indicated” for at least one disease or symptom.  The drug gabapentin, better known by its trade name “Neurontin™”, is FDA- approved “for treatment of partial epilepsy” and for long-lasting nerve irritation – neuralgia – resulting from shingles.  Yet, according to the Medical Letter on Drugs and Therapeutics, Neurontin™ is widely used “off-label”, that is, for many types of chronic pain and other conditions for which the drug is not FDA-approved.

 

For example, published studies suggest that Neurontin™ can control pain seen in some diabetics – so-called “diabetic peripheral neuropathy”.  There have also been reports, published and anecdotal, of Neurontin™’s effectiveness in helping some patients with “other neuropathic pain syndromes, going by names like trigeminal neuralgia, multiple sclerosis, neuropathic head and neck pain and phantom limb pain.  There have also been published studies suggesting that Neurontin™ can be more helpful than placebo in preventing migraine headaches.

 

In addition to using off-label for chronic pain disorders, some physicians have given it to patients to help them deal with social anxiety disorder and even attention deficit disorder – even though, says the Medical Letter, “no good evidence that (it) is effective for mood disorders or attention deficit disorder.

 

Is off-label use of this or any other drug illegal?  No.  Is it unethical?  Not if the physician has a rational reason for trying it and it is safe for the patient.  Indeed, using Neurontin or any drug off-label creates opportunities to discover new uses for drugs whose relative safety has already been documented.  For a copy of this script and the journal reference, access our web site, www.speakingof health.com.  Speaking of Health, I’m Dr. Steven Andrew Davis for CBS News.

 

Ref:  The Medical Letter on Drugs and Therapeutics.  Vol 46. Apr. 12, 2004.  Pages 29 – 31.